Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582664 | 0.81 | MTNR1A (0.57) | MRGPRX4MTNR1AMTNR1B | |
| SCHEMBL3573117 | 0.75 | TRPV1 (0.50) | — | |
| SCHEMBL3585190 | 0.74 | SMN1; SMN2 (0.52) | MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL11667681 | 0.74 | MAOB (0.49) | MRGPRX4NR4A2USP2MEN1ALDH1A1 | |
| SCHEMBL3566335 | 0.73 | SMN1; SMN2 (0.51) | MEN1ALDH1A1KMT2A | |
| SCHEMBL10880786 | 0.72 | HTR1D (0.47) | GPR34MTNR1AMTNR1B | |
| SCHEMBL3577544 | 0.71 | TRPV4 (0.46) | MRGPRX4PPARGPPARAGPR34NR4A2 | |
| SCHEMBL28437354 | 0.71 | PPARG (0.51) | MRGPRX4PPARGPPARAGPR34NR4A2 | |
| SCHEMBL28429123 | 0.71 | PPARG (0.51) | MRGPRX4PPARGPPARAGPR34NR4A2 | |
| SCHEMBL29994776 | 0.71 | PPARG (0.51) | MRGPRX4PPARGPPARAGPR34NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | MRGPRX4 1556/4885ADAMTS4 3574/4885PPARG 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.